Antimanic Drug Use in Pregnancy

NCT00585702•University of Pittsburgh

Summary

The purpose of this study is to learn about the effects of bipolar disorder or the use of antimanic medications on the mother's health and wellbeing during pregnancy and for the first postpartum year. Infant health and development are also assessed during the first year. Participation in the study includes 7 study visits, three in pregnancy and four postpartum.

Eligibility

Age

18 - 45 years

Sex

FEMALE

Healthy Volunteers

Yes

Inclusion Criteria

•Age 18 or older
•Pregnant at 20 weeks or more
•Women must receive OB care
•English-speaking
•DSM-IV diagnosis of BP, any subtype
•Age 18 or older
•Pregnant at 20 weeks or more
•English-speaking
•Women must receive OB care.
•Women may have past or present subclinical Major Depressive Disorder according to the DSM-IV.

Exclusion Criteria

•Women must have no Active Alcohol Abuse or Dependence, Active Abuse or Dependence of Opiates, Inhalants, Amphetamines including Ecstasy or LSD, Active IV Drug Abuse, or Methadone Maintenance.
•Women must not take drugs in the FDA categories D or X.
•Women must have no lifetime history of Bipolar Disorder or antimanic drug use.

Locations (1)

University of Pittsburgh

Pittsburgh, Pennsylvania, United States

Key Dates

Start Date

August 1, 2006

Primary Completion Date

March 1, 2012

Completion Date

March 1, 2012

Last Updated

October 7, 2013

Enrollment

201

ACTUAL participants

Conditions

Bipolar DisorderPregnancy

Mindfulness-based Intervention Prior to External Cephalic Version

NCT06768060

Breech Presentation in PregnancyExternal Cephalic Version

View study

RECRUITINGPHASE4

Effect Clomiphene vs Clomiphene Along With Pioglitazone on Ovarian Stimulation Rate

NCT07462065

Infertility TreatmentPregnancy Rates

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: October 7, 2013Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Antimanic Drug Use in Pregnancy

Inclusion Criteria

Exclusion Criteria

Mindfulness-based Intervention Prior to External Cephalic Version

Effect Clomiphene vs Clomiphene Along With Pioglitazone on Ovarian Stimulation Rate

Comparison of Two Salpingectomy Techniques for Sterilization at the Time of Cesarean Delivery

University of Iowa Interventional Psychiatry Service Patient Registry

Odevixibat Pregnancy and Lactation Surveillance Program: A Study to Evaluate the Safety of Odevixibat During Pregnancy and/or Lactation

Iron Absorption From IFA and MMS Supplements in Kenyan Women During the Second Trimester of Pregnancy